tiprankstipranks
Advertisement
Advertisement
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
PremiumCompany AnnouncementsAurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
1M ago
Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c
Premium
The Fly
Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c
2M ago
Aurinia backs FY26 revenue view $315M-$325M, consensus $326.22M
Premium
The Fly
Aurinia backs FY26 revenue view $315M-$325M, consensus $326.22M
2M ago
Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
PremiumThe FlyAurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
3M ago
Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
Premium
The Fly
Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
3M ago
Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay
Premium
Company Announcements
Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay
3M ago
Aurinia Lifts Profits on LUPKYNIS Growth and Sets Double-Digit 2026 Revenue Outlook
PremiumCompany AnnouncementsAurinia Lifts Profits on LUPKYNIS Growth and Sets Double-Digit 2026 Revenue Outlook
4M ago
Aurinia Lifts Revenue on LUPKYNIS Growth, Sets Strong 2026 Sales Outlook
Premium
Company Announcements
Aurinia Lifts Revenue on LUPKYNIS Growth, Sets Strong 2026 Sales Outlook
4M ago
Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c
Premium
The Fly
Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100